Saturation genome editing of BAP1 functionally classifies somatic and germline variants
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Many variants that we inherit from our parents or acquire de novo or somatically are rare, limiting the precision with which we can associate them with disease. We performed exhaustive saturation genome editing (SGE) of BAP1, the disruption of which is linked to tumorigenesis and altered neurodevelopment. We experimentally characterized 18,108 unique variants, of which 6,196 were found to have abnormal functions, and then used these data to evaluate phenotypic associations in the UK Biobank. We also characterized variants in a large population-ascertained tumor collection, in cancer pedigrees and ClinVar, and explored the behavior of cancer-associated variants compared to that of variants linked to neurodevelopmental phenotypes. Our analyses demonstrated that disruptive germline BAP1 variants were significantly associated with higher circulating levels of the mitogen IGF-1, suggesting a possible pathological mechanism and therapeutic target. Furthermore, we built a variant classifier with >98% sensitivity and specificity and quantify evidence strengths to aid precision variant interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 1×
“Next, we sought to quantify the evidence strength at which predictions from our assay could be applied using the American College of Medical Genetics and Genomics (ACMG) framework for variant interpretation 20 .”
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196
Nextflow enables reproducible computational workflows
Di Tommaso, P., Chatzou, M., Floden, E. W., Barja, P. P., Palumbo, E., & Notredame, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3820 · Cited by 4,001
CADD: predicting the deleteriousness of variants throughout the human genome
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J., & Kircher, M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1016 · Cited by 3,534
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · cited 1×
“However, a synonymous variant (c.936T>G) observed in renal cancers 40 and extensively characterized 41 as loss of function due to exon skipping was found to be depleted in our SGE screen.”
SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File Manipulation
Shen, W., Le, S., Li, Y., & Hu, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163962 · Cited by 3,380
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants
Ioannidis, N. M., Rothstein, J. H., Pejaver, V., Middha, S., McDonnell, S. K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.08.016 · Cited by 2,908
Singularity: Scientific containers for mobility of compute
Kurtzer, G. M., Sochat, V., & Bauer, M. W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177459 · Cited by 2,740
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“Finally, to further explore the use of SGE data and identify novel BAP1 variants, we queried tumor sequence data for a cohort of 394,756 patient samples in the Foundation Medicine database 29 and found 12,172 (3.1”
InfluentialMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
A genomic mutational constraint map using variation in 76,156 human genomes
Chen, S., Francioli, L. C., Goodrich, J. K., Collins, R. L., Kanai, M., Wang, Q., Alföldi, J., Watts, N. A., Vittal, C., Gauthier, L. D., et al. (2024) · Nature · doi:10.1038/s41586-023-06045-0 · Cited by 1,727
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 1×
“BAP1 is somatically mutated in many tumors, with germline variants predisposing to cancer 37–39 and a developmental disorder 9 .”
Accurate classification of BRCA1 variants with saturation genome editing
Findlay, G. M., Daza, R. M., Martin, B., Zhang, M. D., Leith, A. P., Gasperini, M., Janizek, J. D., Huang, X., Starita, L. M., & Shendure, J. (2018) · Nature · doi:10.1038/s41586-018-0461-z · Cited by 843
Disease variant prediction with deep generative models of evolutionary data
Frazer, J., Notin, P., Dias, M., Gomez, A., Min, J. K., Brock, K., Gal, Y., & Marks, D. S. (2021) · Nature · doi:10.1038/s41586-021-04043-8 · Cited by 791
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · cited 1×
“A con-trol construct, pKLV2-U6gRNA5(Empty)-PGKBFP2AGFP-W (Addgene, 67979), was also used with fluorescence-activated cell sorting (FACS) analysis performed on 10,000−20,000 cells for each condition with 405-nm and 488-nm channels for BFP + and GFP + , respectively 57 (see Extended Data Fig.”
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Evidence for 28 genetic disorders discovered by combining healthcare and research data
Kaplanis, J., Samocha, K. E., Wiel, L., Zhang, Z., Arvai, K. J., Eberhardt, R. Y., Gallone, G., Lelieveld, S. H., Martin, H. C., McRae, J. F., et al. (2020) · Nature · doi:10.1038/s41586-020-2832-5 · Cited by 615
Self-citationEvaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens
Hart, T., Tong, A. H. Y., Chan, K., Van Leeuwen, J., Seetharaman, A., Aregger, M., Chandrashekhar, M., Hustedt, N., Seth, S., Noonan, A., et al. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.041277 · Cited by 599
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework
Tavtigian, S. V., Greenblatt, M. S., Harrison, S. M., Nussbaum, R. L., Prabhu, S. A., Boucher, K. M., & Biesecker, L. G. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.210 · Cited by 590 · cited 1×
“These observations equate to likelihood ratios toward pathogenicity of 27.6 and benignity of 470.6, which correspond to strong and very strong evidence strengths, respectively 22,23 .”
InfluentialA joint NCBI and EMBL-EBI transcript set for clinical genomics and research
Morales, J., Pujar, S., Loveland, J. E., Astashyn, A., Bennett, R., Berry, A., Cox, E., Davidson, C., Ermolaeva, O., Farrell, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04558-8 · Cited by 571
Carson, M. J., Behringer, R. R., Brinster, R. L., & McMorris, F. A. (1993) · Neuron · doi:10.1016/0896-6273(93)90173-o · Cited by 474
The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1
Machida, Y. J., Machida, Y., Vashisht, A. A., Wohlschlegel, J. A., & Dutta, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046755 · Cited by 274
Research works printed but not linked: 37
- Star, P. et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur. J. Cancer 92, 48–53 (2018). · DOI
- Chau, C. et al. Families with BAP1-tumor predisposition syndrome in the Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers 11, 1114 (2019). · DOI
- Lalloo, F. et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur. J. Hum. Genet. 31, 1261–1269 (2023). · DOI
- Fennell, D. A. et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir. Med. 9, 593–600 (2021). · DOI
- Pandey, G. K. et al. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep. Med. 4, 100915 (2023). · DOI
- Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
- Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013). · DOI · Paper page
- Küry, S. et al. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder. Am. J. Hum. Genet. 109, 361–372 (2022). · DOI
- Alexander, J., Findlay, G. M., Kircher, M. & Shendure, J. Concurrent genome and epigenome editing by CRISPR-mediated sequence replacement. BMC Biol. 17, 90 (2019). · DOI
- Barbon, L. et al. Variant Library Annotation Tool (VaLiAnT): an oligonucleotide library design and annotation tool for saturation genome editing and other deep mutational scanning experiments. Bioinformatics 38, 892–899 (2022). · DOI
- Radford, E. J. et al. Saturation genome editing of DDX3X clarifies pathogenicity of germline and somatic variation. Nat. Commun. 14, 7702 (2023).
- Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003). · DOI · Paper page
- Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010). · DOI · Paper page
- Brnich, S. E. et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med. 12, 3 (2019).
- O’Shea, S. J. et al. A population-based analysis of germline BAP1 mutations in melanoma. Hum. Mol. Genet. 26, 717–728 (2017).
- Walpole, S. et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J. Natl Cancer Inst. 110, 1328–1341 (2018). · DOI · Paper page
- Backman, J. D. et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature 599, 628–634 (2021). · DOI · Paper page
- Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220.e15 (2017). · DOI · Paper page
- Tung, N. et al. Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing. NPJ Precis. Oncol. 7, 76 (2023).
- Nishikawa, H. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 69, 111–119 (2009). · DOI · Paper page
- Misaghi, S. et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol. Cell. Biol. 29, 2181–2192 (2009). · DOI · Paper page
- Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071–5085 (2010). · DOI · Paper page
- Eletr, Z. M. & Wilkinson, K. D. An emerging model for BAP1’s role in regulating cell cycle progression. Cell Biochem. Biophys. 60, 3–11 (2011). · DOI · Paper page
- Affar, E. B. & Carbone, M. BAP1 regulates different mechanisms of cell death. Cell Death Dis. 9, 1151 (2018). · DOI · Paper page
- Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018–1021 (2011). · DOI · Paper page
- Niersch, J. et al. A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis. iScience 24, 102173 (2021). · DOI
- Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548.e24 (2019). · DOI · Paper page
- Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518 (2004). · DOI · Paper page
- Knuppel, A. et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. Cancer Res. 80, 4014–4021 (2020). · DOI · Paper page
- Riikonen, R. Insulin-like growth factors in the pathogenesis of neurological diseases in children. Int. J. Mol. Sci. 18, 2056 (2017). · DOI
- Hellström, A. et al. Role of insulinlike growth factor 1 in fetal development and in the early postnatal life of premature infants. Am. J. Perinatol. 33, 1067–1071 (2016). · DOI
- Vahdatpour, C., Dyer, A. H. & Tropea, D. Insulin-like growth factor 1 and related compounds in the treatment of childhood-onset neurodevelopmental disorders. Front. Neurosci. 10, 450 (2016). · DOI · Paper page
- de los Robinson-Agramonte, M. A. et al. BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism. Sci. Rep. 12, 13768 (2022).
- Khanbabaei, M. et al. Precocious myelination in a mouse model of autism. Transl. Psychiatry 9, 251 (2019). · DOI
- Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011). · DOI · Paper page
- Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011). · DOI · Paper page
- Lee, C. H., Cook, S., Lee, J. S. & Han, B. Comparison of two meta-analysis methods: inverse-variance-weighted average and weighted sum of z-scores. Genomics Inform. 14, 173–180 (2016). · DOI · Paper page
Cited by
High-resolution functional mapping of RAD51C by saturation genome editing
Olvera-León, R., Zhang, F., Offord, V., Zhao, Y., Tan, H. K., Gupta, P., Pal, T., Robles-Espinoza, C. D., Arriaga-González, F. G., Matsuyama, L. S. A. S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.039 · Cited by 44
“…is of relevance to the Human Genome Variation Society (HGVS) notation used where precedent is given to the 3’ annotations when polynucleotide sequences contain variants, hence the annotation of ‘‘p.Met10fs’’ for frameshifting deletions in the polynucleotide AAA sequence than spans codon 9 and 10.”
BackgroundSelf-citationMaveMD: A functional data resource for genomic medicine
McEwen, A. E., Stone, J., Tejura, M., Gupta, P., Capodanno, B. J., Da, E. Y., Grindstaff, S. B., Moore, N., Reinhart, D., Snyder, A. E., et al. (2025) · doi:10.1101/2025.11.15.25336228 · Cited by 5
“…Olvera-León et al., 2024; O’Neill et al., 2024; Popp 8/30 . et al., 2025; Radford et al., 2023; Sahu et al., 2025, 2023; Shepherdson et al., 2024; Sun et al., 2020; Sung et al., 2024; van Loggerenberg et al., 2023; Wan et al., 2019; Waters et al., 2024; Weile et al., 2017; Zheng et al., 2022).”
Self-citationEditing stem cell genomes at scale to measure variant effects in diverse cell and genetic contexts
Fayer, S., Garge, R. K., Hopkins, M., Friedman, C. E., McGee, A. V., Rico, J., Powell, R. L., McDermot, E., Smith, N. T., Pendyala, S., et al. (2025) · doi:10.1101/2025.11.12.25340127 · Cited by 4
Self-citationProtocol for the functional evaluation of genetic variants using saturation genome editing
Obolenski, S., Olvera-León, R., Sun, D., Adams, D. J., & Waters, A. J. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.103710 · Cited by 3
Self-citation
Metadata
- Authors
- Waters, A. J., Brendler-Spaeth, T., Smith, D., Offord, V., Tan, H. K., Zhao, Y., Obolenski, S., Nielsen, M., van Doorn, R., Murphy, J.-E., Gupta, P., Rowlands, C. F., Hanson, H., Delage, E., Thomas, M., Radford, E. J., Gerety, S. S., Turnbull, C., Perry, J. R. B., Hurles, M. E., & Adams, D. J.
- Venue
- Nature Genetics
- Published
- 2024-07
- Volume
- 56
- Issue
- 7
- Pages
- 1434-1445
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W4400362311
- Cited by
- 57
- References
- 28
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 4 d)
- Funders
- Wellcome Trust (220540/Z/20/A)
- Cancer Research UK (EDDPGM-Nov22/100004)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.